Published in Future Oncol on November 01, 2009
CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma. Clin Cancer Res (2015) 1.42
Dual blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) pathways synergistically inhibits rhabdomyosarcoma cell growth in vitro and in vivo. Clin Cancer Res (2013) 1.37
Rhabdomyosarcoma in adolescent and young adult patients: current perspectives. Adolesc Health Med Ther (2014) 1.28
CD133 positive embryonal rhabdomyosarcoma stem-like cell population is enriched in rhabdospheres. PLoS One (2011) 1.22
Childhood rhabdomyosarcoma: recent advances and prospective views. J Dent Res (2011) 1.06
Furin targeted drug delivery for treatment of rhabdomyosarcoma in a mouse model. PLoS One (2010) 1.00
Targeting the insulin-like growth factor pathway in rhabdomyosarcomas: rationale and future perspectives. Sarcoma (2011) 0.96
MicroRNAs in skeletal muscle biology and exercise adaptation. Free Radic Biol Med (2013) 0.94
Caveolin-1 in sarcomas: friend or foe? Oncotarget (2011) 0.90
Enhancer of zeste homolog 2 (EZH2) in pediatric soft tissue sarcomas: first implications. BMC Med (2011) 0.89
MicroRNAs in rhabdomyosarcoma: pathogenetic implications and translational potentiality. Mol Cancer (2011) 0.88
Rhabdomyosarcomas in aging A/J mice. PLoS One (2011) 0.86
Rhabdomyosarcomas: an overview on the experimental animal models. J Cell Mol Med (2012) 0.84
The role of microRNAs in skeletal muscle health and disease. Front Biosci (Landmark Ed) (2015) 0.84
Rhabdomyosarcoma of the head and neck in children. Contemp Oncol (Pozn) (2015) 0.83
Small molecule inhibition of PAX3-FOXO1 through AKT activation suppresses malignant phenotypes of alveolar rhabdomyosarcoma. Mol Cancer Ther (2013) 0.82
Combined experience of six independent laboratories attempting to create an Ewing sarcoma mouse model. Oncotarget (2016) 0.81
Phosphocaveolin-1 enforces tumor growth and chemoresistance in rhabdomyosarcoma. PLoS One (2014) 0.81
Tumor suppressor genes promote rhabdomyosarcoma progression in p53 heterozygous, HER-2/neu transgenic mice. Oncotarget (2014) 0.81
Genetic prevention of lymphoma in p53 knockout mice allows the early development of p53-related sarcomas. Oncotarget (2014) 0.80
Too much AKT turns PAX3-FKHR dead: a prospect of novel therapeutic strategy for alveolar rhabdomyosarcoma. Oncotarget (2012) 0.80
SRC family kinase (SFK) inhibition reduces rhabdomyosarcoma cell growth in vitro and in vivo and triggers p38 MAP kinase-mediated differentiation. Oncotarget (2015) 0.79
MicroRNAs in soft tissue sarcomas: overview of the accumulating evidence and importance as novel biomarkers. Biomed Res Int (2014) 0.79
The Skin as an Early Expression of Malignancies in the Neonatal Age: A Review of the Literature and a Case Series. Biomed Res Int (2015) 0.79
Calcitriol inhibits hedgehog signaling and induces vitamin d receptor signaling and differentiation in the patched mouse model of embryonal rhabdomyosarcoma. Sarcoma (2012) 0.78
Implications for the mammalian sialidases in the physiopathology of skeletal muscle. Skelet Muscle (2012) 0.78
Structural and functional studies of FKHR-PAX3, a reciprocal fusion gene of the t(2;13) chromosomal translocation in alveolar rhabdomyosarcoma. PLoS One (2013) 0.77
Overexpression of the skNAC gene in human rhabdomyosarcoma cells enhances their differentiation potential and inhibits tumor cell growth and spreading. Clin Exp Metastasis (2014) 0.76
Microenvironmental Targets in Sarcoma. Front Oncol (2015) 0.76
Epigenetic deregulation of microRNAs in rhabdomyosarcoma and neuroblastoma and translational perspectives. Int J Mol Sci (2012) 0.76
LEF1 reduces tumor progression and induces myodifferentiation in a subset of rhabdomyosarcoma. Oncotarget (2016) 0.75
Characterization of FGFR signaling pathway as therapeutic targets for sarcoma patients. Cancer Biol Med (2016) 0.75
Perianal rhabdomyosarcoma presenting 21 months after hamartoma excision. Pediatr Surg Int (2012) 0.75
Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res (2005) 2.09
Vaccines for tumour prevention. Nat Rev Cancer (2006) 1.87
2011: the immune hallmarks of cancer. Cancer Immunol Immunother (2011) 1.66
NVP-BEZ235 as a new therapeutic option for sarcomas. Clin Cancer Res (2010) 1.52
Immunoprevention of HER-2/neu transgenic mammary carcinoma through an interleukin 12-engineered allogeneic cell vaccine. Cancer Res (2004) 1.25
Preclinical in vivo study of new insulin-like growth factor-I receptor--specific inhibitor in Ewing's sarcoma. Clin Cancer Res (2007) 1.25
ImmunoGrid, an integrative environment for large-scale simulation of the immune system for vaccine discovery, design and optimization. Brief Bioinform (2009) 1.19
Modeling the competition between lung metastases and the immune system using agents. BMC Bioinformatics (2010) 1.19
Cure of mammary carcinomas in Her-2 transgenic mice through sequential stimulation of innate (neoadjuvant interleukin-12) and adaptive (DNA vaccine electroporation) immunity. Clin Cancer Res (2005) 1.18
Inhibition of connective tissue growth factor (CTGF/CCN2) expression decreases the survival and myogenic differentiation of human rhabdomyosarcoma cells. Cancer Res (2004) 1.17
In silico modeling and in vivo efficacy of cancer-preventive vaccinations. Cancer Res (2010) 1.17
Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas. J Clin Invest (2003) 1.17
ImmunoGrid: towards agent-based simulations of the human immune system at a natural scale. Philos Trans A Math Phys Eng Sci (2010) 1.16
Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells. Proc Natl Acad Sci U S A (2009) 1.14
CD99 inhibits neural differentiation of human Ewing sarcoma cells and thereby contributes to oncogenesis. J Clin Invest (2010) 1.10
Effectiveness of insulin-like growth factor I receptor antisense strategy against Ewing's sarcoma cells. Cancer Gene Ther (2002) 1.09
Expression of an IGF-I receptor dominant negative mutant induces apoptosis, inhibits tumorigenesis and enhances chemosensitivity in Ewing's sarcoma cells. Int J Cancer (2002) 1.09
Development of rhabdomyosarcoma in HER-2/neu transgenic p53 mutant mice. Cancer Res (2003) 1.08
Antimetastatic activity of a preventive cancer vaccine. Cancer Res (2007) 1.07
Rethinking herpes simplex virus: the way to oncolytic agents. Rev Med Virol (2011) 1.06
Cancer immunoprevention. Future Oncol (2005) 1.05
A better immune reaction to Erbb-2 tumors is elicited in mice by DNA vaccines encoding rat/human chimeric proteins. Cancer Res (2010) 1.05
Immunoprevention of mammary carcinoma in HER-2/neu transgenic mice is IFN-gamma and B cell dependent. J Immunol (2004) 1.04
High metastatic efficiency of human sarcoma cells in Rag2/gammac double knockout mice provides a powerful test system for antimetastatic targeted therapy. Eur J Cancer (2009) 1.00
Vaccination with dendritic cells pulsed with apoptotic tumors in combination with anti-OX40 and anti-4-1BB monoclonal antibodies induces T cell-mediated protective immunity in Her-2/neu transgenic mice. Int J Cancer (2005) 1.00
CD99 acts as an oncosuppressor in osteosarcoma. Mol Biol Cell (2006) 1.00
Multiorgan metastasis of human HER-2+ breast cancer in Rag2-/-;Il2rg-/- mice and treatment with PI3K inhibitor. PLoS One (2012) 0.99
The cytotoxic T-lymphocyte response against a poorly immunogenic mammary adenocarcinoma is focused on a single immunodominant class I epitope derived from the gp70 Env product of an endogenous retrovirus. Cancer Res (2003) 0.99
CD25+ regulatory T cell depletion augments immunotherapy of micrometastases by an IL-21-secreting cellular vaccine. J Immunol (2006) 0.97
Gene expression analysis of immune-mediated arrest of tumorigenesis in a transgenic mouse model of HER-2/neu-positive basal-like mammary carcinoma. Am J Pathol (2005) 0.97
Respiratory complex I is essential to induce a Warburg profile in mitochondria-defective tumor cells. Cancer Metab (2013) 0.96
A mutation threshold distinguishes the antitumorigenic effects of the mitochondrial gene MTND1, an oncojanus function. Cancer Res (2011) 0.95
Insulin-like growth factor binding protein 3 as an anticancer molecule in Ewing's sarcoma. Int J Cancer (2006) 0.95
LAG-3 enables DNA vaccination to persistently prevent mammary carcinogenesis in HER-2/neu transgenic BALB/c mice. Cancer Res (2003) 0.94
The Integrated Oncology Program of the Italian Ministry of Health. Analytical and clinical validation of new biomarkers for early diagnosis: network, resources, methodology, quality control, and data analysis. Int J Biol Markers (2009) 0.93
C-kit receptor expression in Ewing's sarcoma: lack of prognostic value but therapeutic targeting opportunities in appropriate conditions. J Clin Oncol (2003) 0.91
Vaccines and other immunological approaches for cancer immunoprevention. Curr Drug Targets (2011) 0.91
Preclinical therapy of disseminated HER-2⁺ ovarian and breast carcinomas with a HER-2-retargeted oncolytic herpesvirus. PLoS Pathog (2013) 0.89
Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER2. Breast Cancer Res (2014) 0.89
An integrated approach of immunogenomics and bioinformatics to identify new Tumor Associated Antigens (TAA) for mammary cancer immunological prevention. BMC Bioinformatics (2005) 0.88
Up-regulation of EphB and ephrin-B expression in rhabdomyosarcoma. Anticancer Res (2008) 0.88
Prevention of HER-2/neu transgenic mammary carcinoma by tamoxifen plus interleukin 12. Int J Cancer (2003) 0.88
Targeting CD99 in association with doxorubicin: an effective combined treatment for Ewing's sarcoma. Eur J Cancer (2005) 0.87